Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: A SEER analysis

International Braz J Urol

Volumn 41, Issue 2, 2015, Pages 288-294

  Xiao, Wen Jun ^a,b   Zhu, Yao ^a,b   Dai, Bo ^a,b   Zhang, Hai Liang ^a,b   Ye, Ding Wei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Carcinoma, renal cell; Molecular targeted therapy; Nephrectomy; Propensity score; SEER program

Indexed keywords

AGE; AGED; CANCER REGISTRY; CANCER STAGING; CARCINOMA, RENAL CELL; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; PROCEDURES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SECONDARY; SEX DIFFERENCE; SOCIOECONOMICS; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

AGE FACTORS; AGED; CARCINOMA, RENAL CELL; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SEX FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84930843475     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2015.02.15     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. Erratum in: CA Cancer J Clin. 2011;61:134.
2. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007; 109: 1763-8.
3. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008; 14: 288-301.
4. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358: 966-70.
5. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345: 1655-9.
6. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171: 1071-6.
7. Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, Shariat SF, et al. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. Urology. 2009; 74: 837-41.
8. Aben KK, Heskamp S, Janssen-Heijnen ML, Koldewijn EL, van Herpen CM, Kiemeney LA, et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a populationbased study in the Netherlands. Eur J Cancer. 2011; 47: 2023-32.
9. Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer. 2006; 107: 2375-83.
10. Margulis V, Wood CG. Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int. 2009; 103: 150-3.
11. Margulis V, Wood CG, Jonasch E, Matin SF. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep. 2008; 10: 253-8.
12. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, available at: http://seer.cancer.gov/archive/csr/1975_2010/based on November 2012 SEER data submission, posted to the SEER web site. 2013.
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-34. Erratum in: N Engl J Med. 2007;357:203.
14. Snow G: Sensitivity analysis for Observational studies. Available at: http://cran.r-project.org/web/packages/obsSens/obsSens.pdf
15. Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr Urol Rep. 2012; 13: 38-46.
16. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011; 185: 60-6.
17. You D, Jeong IG, Ahn JH, Lee DH, Lee JL, Hong JH, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011; 185: 54-9.
18. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007; 177: 855-60; discussion 860-1.
19. Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG. Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol. 2012; 188: 2077-83.
20. Thomas K, David G, Christopher PE, Andrea T: Current and Future Trends in the Treatment of Renal Cancer. Eur urol suppl. 2007; 6: 374-84.
21. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24.
22. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 832-41.
23. Lin DY, Psaty BM, Kronmal RA: Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998; 54: 948-63.
24. Carmena. Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Available at: https://clinicaltrials.gov/ct2/show/NCT00930033?term=renal+cance r&recr=Open&intr=nephrectomy&rank=2. accessed in 2009.